Hong Kong, 26 Aug 2024
    
Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that the Group is humbled and honoured to be included in 2024 Forbes Asia’s Best Under A Billion list for the 3rd time - a testimony to the Group’s achievements over the past few years.  
   
This list features companies with a track record of long-term sustainable performance across a variety of metrics. These 200 companies were selected from a universe of more than 20,000 publicly traded companies in the Asia-Pacific region with annual sales above $10 million and below $1 billion. The companies were selected based on a composite score using measures such as debt, sales and earnings-per-share growth over both the most recent fiscal one- and three-year periods, and the strongest one- and five-year average return on equity.
    
Once again, being listed on the Forbes Asia’s Best Under A Billion list is an encouragement to the Group, and we express sincere gratitude to those who have long supported the Group's development. In the future, we will continue to embrace pragmatic innovation, focusing on meeting unmet clinical needs, particularly in areas of ophthalmology, surgical and wound care, enhancing market expansion and sustainable growth for the company - creating greater value for shareholders.
   
   

~ End ~

   
About ‘Forbes’ List Methodology (Source: forbes.com)
This list features companies with a track record of long-term sustainable performance across a variety of metrics. These 200 companies were selected from a universe of more than 20,000 publicly traded companies in the Asia-Pacific region with annual sales above $10 million and below $1 billion. The companies on this unranked list were selected based on a composite score using measures such as debt, sales and earnings-per-share growth over both the most recent fiscal one- and three-year periods, and the strongest one- and five-year average return on equity. Aside from quantitative criteria, qualitative screens were applied as well, such as excluding companies with serious governance issues, questionable accounting practices, environmental concerns, management problems or legal troubles in recent years. State-controlled entities and subsidiaries of larger companies were also excluded. The criteria sought to ensure a geographical diversity of companies from across the region. The list uses annual results based on the latest publicly available figures as of July 7, 2024.
   
About Essex
Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(適麗順®) (Iodized Lecithin Capsules) and others, which are principally prescribed for wounds healing and diseases in Ophthalmology and Dermatology.
These products are marketed and sold through approximately 13,500 hospitals, supported by the Company’s 43 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex Bio-Technology maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.